Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$69.69K$69.69K+55.0% vs Q1 2019 Net Income$4.34M$4.34MN/M vs Q1 2019 EPS Diluted-$0.14-$0.14N/M vs Q1 2019 Gross Profit$63,425+70.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flow-$297,215N/M Margins · derivedGross margin91.0%+8.2 pt vs Q1 2019
Operating margin-975.3%+833.3 pt vs Q1 2019
Net margin6225.8%+11578.6 pt vs Q1 2019
ended Mar 31, 2020 · filed Jun 12, 2020 · 73 d after period end